4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 556 and 558

[Docket No. FDA-2014-N-0002]

Zoetis Inc., et al.; Withdrawal of Approval of New Animal Drug Applications for Combination Drug Medicated Feeds Containing an Arsenical Drug

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendments.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the withdrawal of approval of 69 new animal drug applications (NADAs) and 22 abbreviated new animal drug applications (ANADAs) for use of arsanilic acid, carbarsone, or roxarsone Type A medicated articles to manufacture combination drug Type B and Type C medicated feeds. This action is being taken at the sponsor's request because the products are no longer manufactured or marketed. FDA is also amending the animal drug regulations to remove entries describing conditions of use for combination drug medicated feeds for which no NADA is approved. This action is being taken to improve the accuracy of the regulations.

DATES: This rule is effective [INSERT DATE 10 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER].

FOR FURTHER INFORMATION CONTACT: John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, john.bartkowiak@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Recently, the Agency provided notice of the withdrawal of approval of NADAs for Type A medicated articles containing arsanilic acid, carbarsone, and roxarsone and revoked applicable regulations for their conditions of use to manufacture single-ingredient medicated feeds in 21 CFR part 558 New Animal Drugs For Use in Animal Feeds (78 FR 70062, Nov. 22, 2013; 78 FR 69992, Nov. 22, 2013; 78 FR 70566, Nov. 26, 2013; 78 FR 70496, Nov. 26, 2013).

Subsequently, the following six sponsors of NADAs and ANADAs permitting use of arsanilic acid, carbarsone, or roxarsone Type A medicated articles to manufacture combination drug Type B and Type C medicated feeds requested that FDA withdraw approval of their applications because these combination medicated feeds are no longer manufactured or marketed.

 Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 has requested that FDA withdraw approval of the following 39 NADAs and 11 ANADAs:

NADA/ ANADA	Ingredient New Animal Drugs
040-435	3-NITRO (roxarsone)/DECCOX (decoquinate)
041-178	Roxarsone/AMPROL Plus (amprolium and ethopabate)/LINCOMIX (lincomycin)
041-984	Roxarsone/ROFENAID (sulfadimethoxine/ormetoprim)
091-326	3-NITRO (roxarsone)/DECCOX (decoquinate)/ALBAC (bacitracin zinc)
092-522	Roxarsone/COBAN (monensin)/LINCOMIX (lincomycin)
095-546	Roxarsone/ROBENZ (robenidine)
102-485	3-NITRO (roxarsone)/AVATEC (lasalocid)
105-758	3-NITRO (roxarsone)/AMPROL HI-E (amprolium and ethopabate)/BACIFERM (bacitracin zinc)
112-661	3-NITRO (roxarsone)/AVATEC (lasalocid)/LINCOMIX (lincomycin)
112-687	3-NITRO (roxarsone)/AVATEC (lasalocid)/FLAVOMYCIN (bambermycins)
116-082	3-NITRO (roxarsone)/AVATEC (lasalocid)/BMD (bacitracin MD)
116-088	3-NITRO (roxarsone)/COBAN (monensin)/BMD (bacitracin MD)
123-154	3-NITRO (roxarsone)/BACIFERM (bacitracin zinc)/COBAN (monensin)

NADA/ ANADA	Ingredient New Animal Drugs			
126-052	3-NITRO (roxarsone)/AVATEC (lasalocid)/BACIFERM (bacitracin zinc)			
131-894	3-NITRO (roxarsone)/AVATEC (lasalocid)/bacitracin MD			
132-447	Roxarsone/BIO-COX (salinomycin)			
134-185	3-NITRO (roxarsone)/BIO-COX (salinomycin)/FLAVOMYCIN (bambermycins)			
135-321	3-NITRO (roxarsone)/BIO-COX (salinomycin)/BMD (bacitracin MD)			
137-536	3-NITRO (roxarsone)/BIO-COX/ALBAC (bacitracin zinc)			
138-703	3-NITRO (roxarsone)/COBAN (monensin)/ALBAC (bacitracin zinc)			
139-190	3-NITRO (roxarsone)/BIO-COX (salinomycin)/BACIFERM (bacitracin zinc)			
140-581	3-NITRO (roxarsone)/BIO-COX (salinomycin)/LINCOMIX (lincomycin)			
140-852	3-NITRO (roxarsone)/MONTEBAN/BMD (bacitracin MD)			
140-867	3-NITRO (roxarsone)/BIO-COX (salinomycin)/AUREOMYCIN (chlortetracycline)			
141-100	3-NITRO (roxarsone)/DECCOX (decoquinate)/BMD (bacitracin MD)			
141-112	3-NITRO (roxarsone)/MAXIBAN (narasin and nicarbazin)/BMD (bacitracin MD)			
141-121	3-NITRO (roxarsone)/BIO-COX (salinomycin)/BMD (bacitracin MD)			
141-131	3-NITRO (roxarsone)/ZOAMIX (zoalene)/BMD (bacitracin MD)			
141-135	3-NITRO (roxarsone)/BIO-COX (salinomycin)			
141-138	3-NITRO (roxarsone)/COBAN (monensin)/BMD (bacitracin MD)			
141-139	3-NITRO (roxarsone)/COBAN (monensin)			
141-142	3-NITRO (roxarsone)/AMPROL (amprolium)/BMD (bacitracin MD)			
141-155	3-NITRO (roxarsone)/ROBENZ (robenidine)/BMD (bacitracin MD)			
141-157	3-NITRO (roxarsone)/STENOROL (halofuginone)			
141-223	3-NITRO (roxarsone)/CLINACOX (diclazuril)			
141-293	3-NITRO (roxarsone)/AVATEC (lasalocid)			
200-206	3-NITRO (roxarsone)/ALBAC (bacitracin zinc)/DECCOX (decoquinate)			
200-207	3-NITRO (roxarsone)/ALBAC (bacitracin zinc)/COYDEN 25 (clopidol)			
200-208	3-NITRO (roxarsone)/ALBAC (bacitracin zinc)/AVATEC (lasalocid)			
200-209	3-NITRO (roxarsone)/ALBAC (bacitracin zinc)/SACOX (salinomycin)			
200-214	3-NITRO (roxarsone)/ALBAC (bacitracin zinc)/AMPROL HI-E (amprolium and ethopabate)			
200-211	3-NITRO (roxarsone)/ALBAC (bacitracin zinc)/COBAN (monensin)			
200-215	3-NITRO (roxarsone)/ALBAC (bacitracin zinc)/BIO-COX (salinomycin)			
200-217	3-NITRO (roxarsone)/ALBAC (bacitracin zinc)/AMPROL HI-E (amprolium and ethopabate)			
200-259	3-NITRO (roxarsone)/SACOX (salinomycin)/CHLORMAX (chlortetracycline)			
200-260	3-NITRO (roxarsone)/BIO-COX (salinomycin)/CHLORMAX (chlortetracycline)			

NADA/ ANADA	Ingredient New Animal Drugs
038-879	CARB-O-SEP (carbarsone)/ZOAMIX (zoalene)
039-646	CARB-O-GAIN (carbarsone)/BMD (bacitracin MD)
136-484	CARB-O-SEP (carbarsone)/BACIFERM (bacitracin zinc)
200-203	CARB-O-SEP (carbarsone)/ALBAC (bacitracin zinc)

• Huvepharma AD, 5th Floor, 3A Nikolay Haitov Str., 1113 Sofia, Bulgaria, has requested that FDA withdraw approval of the following 16 NADAs and 8 ANADAs:

NADA/ ANADA	Ingredient New Animal Drugs			
013-461	3-NITRO (roxarsone)/AMPROL Plus (amprolium and ethopabate)			
040-264	3-NITRO (roxarsone)/COYDEN 25 (clopidol)			
041-541	3-NITRO (roxarsone)/COYDEN 25 (clopidol)/BMD (bacitracin MD)			
044-016	Roxarsone + bacitracin Zinc/COYDEN 25 (clopidol)			
049-179	Roxarsone/AMPROL HI-E (amprolium and ethopabate)			
049-180	Roxarsone/AMPROL HI-E (amprolium and ethopabate)/BMD (bacitracin MD)			
095-547	3-NITRO (roxarsone)/AMPROL HI-E (amprolium and ethopabate)/FLAVOMYCIN (bambermycins)			
095-548	3-NITRO (roxarsone)/AMPROL (amprolium)/FLAVOMYCIN (bambermycins)			
095-549	3-NITRO (roxarsone)/AMPROL (amprolium)/FLAVOMYCIN (bambermycins)			
098-341	3-NITRO (roxarsone)/COBAN (monensin)/FLAVOMYCIN (bambermycins)			
101-628	3-NITRO (roxarsone)/FLAVOMYCIN (bambermycins)/zoalene			
140-533	3-NITRO (roxarsone)/STENOROL (halofuginone)/BMD (bacitracin MD)			
140-843	3-NITRO (roxarsone)/MONTEBAN (narasin)/FLAVOMYCIN (bambermycins)			
141-190	3-NITRO (roxarsone)/LINICOX (diclazuril)/BMD (bacitracin MD)			
200-080	3-NITRO (roxarsone)/SACOX (salinomycin)/FLAVOMYCIN (bambermycins)			
200-081	3-NITRO (roxarsone)/SACOX (salinomycin)/BMD (bacitracin MD)			
200-086	3-NITRO (roxarsone)/SACOX (salinomycin)/ALBAC (bacitracin zinc)			
200-090	3-NITRO (roxarsone)/SACOX (salinomycin)/LINCOMIX (lincomycin)			

200-091	3-NITRO (roxarsone)/SACOX (salinomycin)/AUREOMYCIN (chlortetracycline)
200-094	3-NITRO (roxarsone)/SACOX (salinomycin)/STAFAC (virginiamycin)
200-097	3-NITRO (roxarsone)/SACOX (salinomycin)
200-143	3-NITRO (roxarsone)/SACOX (salinomycin)/BACIFERM (bacitracin zinc)
118-507	CARB-O-SEP (carbarsone)/AMPROL (amprolium)
130-661	CARB-O-SEP (carbarsone)/FLAVOMYCIN (bambermycins)

• Phibro Animal Health Corp., GlenPointe Centre East, 3d floor, 300 Frank W. Burr Blvd., suite 21, Teaneck, NJ 07666 has requested that FDA withdraw approval of the following seven NADAs and two ANADAs:

NADA/ ANADA	Ingredient New Animal Drugs		
107-997	Roxarsone/NICARB (nicarbazin)/LINCOMIX (lincomycin)		
108-115	Roxarsone/NICARB (nicarbazin)		
120-724	3-NITRO (roxarsone)/STAFAC (virginiamycin)/COBAN (monensin)		
138-953	3-NITRO (roxarsone)/STAFAC (virginiamycin)/BIO-COX (salinomycin)		
141-058	3-NITRO (roxarsone)/AVIAX (semduramycin)/BMD (bacitracin MD)		
141-066	3-NITRO (roxarsone)/AVIAX (semduramycin)		
141-226	Roxarsone/AVIAX (semduramycin)/STAFAC (virginiamycin)		
200-170	3-NITRO (roxarsone)/NICARMIX 25 (nicarbazin)/LINCOMIX (lincomycin)		
200-172	3-NITRO (roxarsone)/NICARMIX 25 (nicarbazin)		

• Elanco Animal Health, A Division of Eli Lilly & Co., Lilly Corporate Center,
Indianapolis, IN 46285 has requested that FDA withdraw approval of the following four
NADAs:

NADA	Ingredient New Animal Drugs		
041-500	3-NITRO (roxarsone)/COBAN (monensin)		
049-464	Roxarsone/monensin/bacitracin		
140-445	Roxarsone/MONTEBAN (narasin)		
141-113	3-NITRO (roxarsone)/MAXIBAN (narasin and nicarbazin)		

• Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland, has requested that FDA withdraw approval of the following three NADAs:

NADA	Ingredient New Animal Drugs		
038-241	PRO-GEN (arsanilic acid)/ERYTHRO (erythromycin)/zoalene		
038-242	PRO-GEN (arsanilic acid)/ERYTHRO (erythromycin)/amprolium + ethopabate		
038-624	PRO-GEN (arsanilic acid)/ERYTHRO (erythromycin)		

• Pennfield Oil Co., 14040 Industrial Rd., Omaha, NE 68144 has requested that FDA withdraw approval of the following ANADA:

ANADA	Ingredient New Animal Drugs
200-355	3-NITRO (roxarsone)/PENNCHLOR (chlortetracycline)/BIO-COX (salinomycin)

Elsewhere in this issue of the <u>Federal Register</u>, FDA gave notice that approval of these NADAs and ANADAs, and all supplements and amendments thereto, is withdrawn, effective [INSERT DATE 10 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL

7

<u>REGISTER</u>]. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these voluntary withdrawals of approval.

In addition, FDA has noticed that certain sections in part 558 contain entries describing conditions of use for combination drug medicated feeds for which no NADA is approved. These errors were introduced by the Agency during the 1976 recodification of certain food additive regulations (41 FR 10984, March 15, 1976). That rule did not identify whether particular regulations were the subject of an approved NADA and consequently resulted in codification of certain conditions of use for which there is no approved NADA. At this time, the Agency is amending the regulations to remove entries that describe conditions of use for combination drug medicated feeds for which no NADA is approved. This action is being taken to improve the accuracy of the regulations.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects

21 CFR Parts 556

Animal drugs, Food.

21 CFR Parts 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 556 and 558 are amended as follows:

PART 556--TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

1. The authority citation for 21 CFR part 556 continues to read as follows:

Authority: 21 U.S.C. 342, 360b, 371.

2. Revise § 556.60 to read as follows:

§ 556.60 Arsenic.

- (a) [Reserved]
- (b) <u>Tolerances</u>. The tolerances for total residue of combined arsenic (calculated as As) are:
 - (1) <u>Turkeys</u>--(i) <u>Muscle and eggs</u>: 0.5 parts per million (ppm).
 - (ii) Other edible tissues: 2 ppm.
 - (2) [Reserved]
 - (c) Related conditions of use. See § 558.369 of this chapter.

PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

3. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

§ 558.4 [Amended]

- 4. In § 558.4, in paragraph (d), in the "Category II" table:
- a. Remove the entries for "Arsanilate acid", "Carbarsone", and "Sulfaquinoxaline";
- b. Remove the row entries under "Nitarsone" for "Sulfanitran" and "Roxarsone".
- c. Remove the four entries for "Roxarsone" and their respective following row entries; and
- d. In the fourth entry for "Sulfamethazine," remove its three following row entries for "Aklomide" and two following row entries for "Roxarsone".
- 5. In § 558.55, revise paragraphs (d)(1) through (3) and add paragraph (d)(4) to read as follows:

§ 558.55 Amprolium.

* * * * *

(d) * * *

(1) <u>Cattle</u>. It is used as follows:

Amprolium in grams	Indications for use	Limitations	Sponsor
per ton			
(i) 113.5 to 11, 350; to provide 5 milligrams per kilogram of body weight per day.	Calves: As an aid in the prevention of coccidiosis caused by Eimeria bovis and E. zuernii.	Top-dress on or mix in the daily ration. Feed for 21 days when experience indicates that coccidiosis is likely to be a hazard, as the sole source of amprolium. Withdraw 24 hours before slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be	016592
		processed for yeal.	
(ii) 113.5 to 11, 350; to provide 10 milligrams per kilogram of body weight per day.	Calves: As an aid in the treatment of coccidiosis caused by <u>Eimeria bovis</u> and <u>E. zuernii</u> .	Top-dress on or mix in the daily ration. Feed for 5 days as the sole source of amprolium. Withdraw 24 hours before slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.	016592

(2) Chickens. It is used as follows:

Amprolium in	rolium in Combination in Indications for use		Limitations	Sponsor
grams per ton	grams per ton			
(i) 36.3 to 113.5		Replacement chickens: For	Feed continuously until	016592
		development of active immunity to	onset of production as	
		coccidiosis.	follows:	

Growing conditions	Up to 5 weeks of age	From 5 to 8 weeks of age	Over 8 weeks of age
	Amprolium in	Amprolium in	Amprolium in
	grams per ton	grams per ton	grams per ton
Severe exposure to coccidiosis.	113.5	72.6-113.5	36.3-113.5
_	(0.0125%)	(0.008%-0.0125%)	(0.004%-0.0125%)
Moderate exposure to coccidiosis.	72.6-113.5	54.5-113.5	36.3-113.5
_	(0.008%-0.0125%)	(0.006%-0.0125%)	(0.004%-0.0125%)
Slight exposure to coccidiosis.	36.3-113.5	36.3-113.5	36.3-113.5
	(0.004%-0.0125%)	(0.004%-0.0125%)	(0.004%-0.0125%)

Amprolium in	Combination in	Indications for use	Limitations	Sponsor
grams per ton	grams per ton			
(ii) 36.3 to 113.5	Bacitracin	Replacement chickens: For	Feed according to subtable in	054771
	methylene	development of active immunity	item (i). Bacitracin methylene	
	disalicylate 4 to	to coccidiosis; and for increased	disalicylate as provided by No.	

Amprolium in	Combination in	Indications for use	Limitations	Sponsor
grams per ton	grams per ton			
	50	rate of weight gain and improved	054771 in § 510.600(c) of this	
		feed efficiency.	chapter.	
(iii) 72.6 to 113.5		Broiler chickens: For prevention	Feed continuously as the sole	016592
		of coccidiosis caused by Eimeria	ration; as sole source of	
		tenella only.	amprolium.	
(iv) 72.6 to 113.5	Bambermycins 1	Broiler chickens: For prevention	Feed continuously as the sole	016592
	to 2	of coccidiosis caused by Eimeria	ration; as sole source of	
		tenella only; and for increased	amprolium. Bambermycins as	
		rate of weight gain and improved	provided by No. 016592 in	
		feed efficiency.	§ 510.600(c) of this chapter.	
(v) 113.5		1. Laying chickens: For	Feed continuously as the sole	016592
(V) 113.3	•••••	prevention of coccidiosis.	ration; as the sole source of	010372
		prevention of coccidiosis.	amprolium.	
		2 I sain a shi shana. Fan taratarant	Feed for 2 weeks.	
		2. Laying chickens: For treatment	reed for 2 weeks.	
		of coccidiosis in moderate		
		outbreaks.		04.470.5
(vi) 113.5 to 227		1. Replacement chickens: For	Feed continuously from day-old	016592
		prevention of coccidiosis where	until onset of production; as the	
		immunity to coccidiosis is not	sole source of amprolium.	
		desired.		
		2. Broiler chickens: For	Feed continuously as the sole	
		prevention of coccidiosis where	ration; as sole source of	
		immunity to coccidiosis is not	amprolium.	
		desired.		
(vii) 113.5 to 227	Bambermycins 1	Broiler chickens: For prevention	Feed continuously as the sole	016592
(, , ===== == === , ==== , ==== , ==== , ==== , ==== , ==== , ==== , ==== , ==== , ==== , ==== , ===== , ====	to 2	of coccidiosis where immunity to	ration; as sole source of	
	102	coccidiosis is not desired; and for	amprolium. Bambermycins as	
		increased rate of weight gain and	provided by No. 016592 in	
		improved feed efficiency.	§ 510.600(c) of this chapter.	
(viii) 227		Laying chickens: For treatment of	Feed for 2 weeks.	016592
(viii) 227	•••••	coccidiosis in severe outbreaks.	reed for Z weeks.	010392
		coccidiosis in severe outbreaks.		

(3) <u>Turkeys</u>. It is used as follows:

Amprolium in	Combination in	Indications for use	Limitations	Sponsor
grams per ton	grams per ton			
(i) 113.5	Bambermycins 1 to 4	Growing turkeys: For prevention of coccidiosis; and for increased rate of weight gain and improved feed efficiency.	Feed continuously as the sole source of amprolium; bambermycins as provided by No. 016592 in § 510.600(c) of this chapter.	016592
(ii) 113.5 to 227		Turkeys: For prevention of coccidiosis.	Feed continuously as the sole ration; as sole source of amprolium.	016592

(4) <u>Pheasants</u>. It is used as follows:

Amprolium in	Combination in	Indications for use	Limitations	Sponsor
grams per ton	grams per ton			
(i) 159		Growing pheasants: For the prevention of coccidiosis caused by Eimeria colchici, E. duodenalis, and E. phasiani.	Feed continuously as sole ration. Use as sole source of amprolium.	016592
(ii) [Reserved]				

6. In § 558.58, revise paragraph (e) to read as follows:

§ 558.58 Amprolium and ethopabate.

* * * * *

(e) Conditions of use. It is used in chicken feed as follows:

Amprolium and ethopabate in	Combination in grams per ton	Indications for use	Limitations	Sponsor
grams per ton (1) Amprolium 113.5 and ethopabate 3.6		Broiler chickens: As an aid in the prevention of coccidiosis.	Feed continuously as sole ration; as sole source of amprolium. Not for laying chickens.	016592
(2) Amprolium 113.5 and ethopabate 3.6	Lincomycin 2 to 4	Broiler chickens: As an aid in the prevention of coccidiosis; for increased rate of weight gain and improved feed efficiency.	Feed continuously as sole ration; as sole source of amprolium. Not for laying chickens. Lincomycin as provided by No. 054771 in § 510.600(c) of this chapter.	054771
(3) Amprolium 113.5 and ethopabate 36.3		Broiler chickens and replacement chickens: where immunity to coccidiosis is not desired: As an aid in the prevention of coccidiosis where severe exposure to coccidiosis from Eimeria acervulina, E. maxima, and E. brunetti is likely to occur.	Feed continuously as sole ration; as sole source of amprolium. Not for chickens over 16 weeks of age.	016592
(4) Amprolium 113.5 and ethopabate 36.3	Bacitracin 4 to 50	1. Broiler chickens and replacement chickens: where immunity to coccidiosis is not desired; to aid in prevention of coccidiosis where severe exposure to coccidiosis from Eimeria	Feed as the sole ration from the time chickens are placed on litter until past the time when coccidiosis is ordinarily a hazard. Not for chickens over 16 weeks of age; do not feed to laying chickens; as sole source of amprolium; not for	016592

		acervulina, E. maxima, and E. brunetti is likely to occur; for increased rate of weight gain in	use as a treatment for outbreaks of coccidiosis. Bacitracin as bacitracin methylene disalicylate as	
		broiler chickens raised in floor pens.	provided by No. 054771 in § 510.600(c) of this chapter.	
(5) Amprolium 113.5 and ethopabate 36.3	Bacitracin 4 to 50	2. Broiler chickens: As an aid in prevention of coccidiosis where severe exposure to coccidiosis from Eimeria acervulina, E. maxima, and E. brunetti is likely to occur; for improved feed efficiency.	Feed as the sole ration from the time chickens are placed on litter until market weight. Not for chickens over 16 weeks of age; do not feed to laying chickens; as sole source of amprolium; not for use as a treatment for coccidiosis. Bacitracin zinc as provided by No. 054771 in § 510.600(c) of this chapter.	054771
(6) Amprolium 113.5 and ethopabate 3.6	Bambermycins 1 to 3	Broiler chickens: As an aid in the prevention of coccidiosis where severe exposure to coccidiosis from Eimeria acervulina, E. maxima, and E. brunetti is likely to occur; for increased rate of weight gain, improved feed efficiency.	Feed continuously as the sole ration; as sole source of amprolium. Bambermycins as provided by No. 016592 in § 510.600(c) of this chapter.	016592
(7) Amprolium 113.5 and ethopabate 36.3	Virginiamycin 15	Broiler chickens; as an aid in the prevention of coccidiosis where severe exposure to coccidiosis from Eimeria acervulina, E. maxima, and E. brunetti is likely to occur; for increased rate of weight gain and improved feed efficiency.	Feed continuously as the sole ration; as sole source of amprolium. Do not feed to laying chickens. Not for chickens over 16 weeks of age. Virginiamycin as provided by No. 066104 in § 510.600(c) of this chapter.	066104
(8) Amprolium 113.5 and ethopabate 36.3	Virginiamycin 5 to 15	Broiler chickens; as an aid in the prevention of coccidiosis where severe exposure to coccidiosis from Eimeria acervulina, E. maxima, and E. brunetti is likely to occur; for increased rate of weight gain.	Feed continuously as the sole ration; as sole source of amprolium. Do not feed to laying chickens. Not for chickens over 16 weeks of age. Virginiamycin as provided by No. 066104 in § 510.600(c) of this chapter.	066104
(9) Amprolium 227 and ethopabate 3.6		For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of	Not for laying chickens.	016592

		coccidiosis.		
(10) Amprolium 227 and ethopabate 3.6	Chlortetracycline 100 to 200	For chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline.	Do not feed to chickens producing eggs for human consumption. Feed for 7 to 14 days.	054771
(11) Amprolium 227 and ethopabate 3.6	Chlortetracycline 200 to 400	For chickens where immunity to coccidiosis is not desired; prevention of coccidiosis; control of chronic respiratory disease (CRD) and air sac infection caused by M. gallisepticum and E. coli susceptible to chlortetracycline.	In low calcium feed containing 0.8% dietary calcium and 1.5% sodium sulfate; feed continuously as sole ration for 7 to 14 days; do not feed to chickens producing eggs for human consumption.	054771

§ 558.62 [Removed]

- 7. Remove § 558.62.
- 8. In § 558.76, revise paragraph (d)(3) to read as follows:

§ 558.76 Bacitracin methylene disalicylate.

* * * * *

- (d) * * *
- (3) Bacitracin methylene disalicylate may also be used in combination with:
- (i) Amprolium as in § 558.55.
- (ii) Amprolium and ethopabate as in § 558.58.
- (iii) Decoquinate as in § 558.195.
- (iv) Diclazuril as in § 558.198.
- (v) Fenbendazole as in § 588.258.
- (vi) Halofuginone as in § 558.265.
- (vii) Hygromycin B as in § 588.274.

- (viii) Ivermectin as in § 558.300.
- (ix) Lasalocid sodium as in § 558.311.
- (x) Monensin as in § 588.355.
- (xi) Narasin as in § 558.363.
- (xii) Nicarbazin alone and with narasin as in § 558.366.
- (xiii) Nitarsone as in § 558.369.
- (xiv) Robenidine as in § 558.515.
- (xv) Salinomycin as in § 558.550.
- (xvi) Semduramicin as in § 558.555.
- (xvii) Zoalene as in § 558.680.
- 9. In § 558.78, revise paragraph (d)(3) to read as follows:

§ 558.78 Bacitracin zinc.

* * * * *

- (d) * * *
- (3) Bacitracin zinc may also be used in combination with:
- (i) Amprolium and ethopabate as in § 558.58.
- (ii) Clopidol as in § 558.175.
- (iii) Decoquinate as in § 558.195.
- (iv) Lasalocid as in § 558.311.
- (v) Monensin as in § 558.355.
- (vi) Naracin as in § 558.363.
- (vii) Nitarsone as in §558.369.
- (viii) Robenidine as in § 558.515.

- (ix) Salinomycin as in § 558.550.
- 10. In § 558.95, revise paragraph (d)(5) to read as follows:

§ 558.95 Bambermycins.

* * * * *

- (d) * * *
- (5) Bambermycins may also be used in combination with:
- (i) Amprolium as in § 558.55.
- (ii) Amprolium and ethopabate as in § 558.58.
- (iii) Clopidal as in § 558.175.
- (iv) Diclazuril as in § 558.198.
- (v) Halofuginone as in § 558.265.
- (vi) Lasalocid as in § 558.311.
- (vii) Monensin as in § 558.355.
- (viii) Narasin alone or with nicarbazin as in § 558.363.
- (ix) Nicarbazin as in § 558.366.
- (x) Salinomycin as in § 558.550.
- (xi) Zoalene as in § 558.680.

§ 558.120 [Removed]

- 11. Remove § 558.120.
- 12. In § 558.128, revise paragraph (e)(7) to read as follows:

§ 558.128 Chlortetracycline.

* * * * *

(e) * * *

- (7) Chlortetracycline may also be used in combination with:
- (i) Amprolium and ethopabate as in § 558.58.
- (ii) Bacitracin methylene disalicylate as in § 558.76.
- (iii) Clopidol as in § 558.175.
- (iv) Decoquinate as in § 558.195.
- (v) Hygromycin B as in § 558.274.
- (vi) Laidlomycin as in § 558.305.
- (vii) Lasalocid as in § 558.311.
- (viii) Monensin as in § 558.355.
- (ix) Robenidine as in § 558.515.
- (x) Salinomycin as in § 558.550.
- (xi) Tiamulin as in § 558.600.

§ 558.175 [Amended]

13. In § 558.175, remove paragraphs (d)(3) and (8); and redesignate paragraphs (d)(4) through (7) as paragraphs (d)(3) through (6), respectively, and paragraphs (d)(9) through (11) as paragraphs (d)(7) through (9), respectively.

§ 558.195 [Amended]

14. In § 558.195, remove paragraphs (e)(1)(iv) and (v) and redesignate paragraphs (e)(1)(vi) through (ix) as paragraphs (e)(1)(iv) through (vii), respectively.

§ 558.198 [Amended]

- 15. In § 558.198, remove paragraphs (d)(1)(iii), (iv), and (vi) and redesignate paragraphs (d)(1)(v), (vii), and (viii) as paragraphs (d)(1)(iii), (iv), and (v), respectively.
 - 16. In § 558.248, remove paragraph (d)(3); and revise the section heading to read as

follows:

§ 558.248 Erythromycin.

* * * * *

17. In § 558.265, remove and reserve paragraphs (d)(1)(v) and (viii) and (d)(3)(ii) and revise the section heading to read as follows:

§ 558.265 Halofuginone.

* * * * *

18. Revise § 558.274 to read as follows:

§ 558.274 Hygromycin B.

- (a) <u>Approvals</u>. See sponsor numbers in § 510.600(c) of this chapter for Type A medicated articles or Type B medicated feeds as follow:
 - (1) No. 000986: 2.4 and 8 grams per pound (g/lb).
 - (2) Nos. 012286 and 051311: 2.4 g/lb.
 - (3) No. 017790: 0.6 g/lb.
 - (4) No. 054771: 0.6 and 1.6 g/lb.
 - (b) Related tolerances. See § 556.330 of this chapter.
 - (c) Conditions of use. It is used in feed as follows:
 - (1) Chickens--

Hygromycin B in	Combination in	Indications for use	Limitations	Sponsor
grams per ton	grams per ton			
(i) 8 to 12		Chickens: For control of	Withdraw 3 days before	000986
		infestation of large roundworms	slaughter.	012286
		(Ascaris galli), cecal worms		017790
		(Heterakis gallinae), and capillary		054771
		worms (Capillaria obsignata).		
(ii) 8 to 12	Tylosin 4 to 50	Chickens: For control of	Withdraw 3 days before	000986
		infestations of large roundworms	slaughter. Tylosin as tylosin	
		(Ascaris galli), cecal worms	phosphate as provided by No.	

Hygromycin B in	Combination in	Indications for use	Limitations	Sponsor
grams per ton	grams per ton			
		(Heterakis gallinae), and capillary	000986 in § 510.600 of this	
		worms (Capillaria obsignata);	chapter.	
		growth promotion and feed	-	
		efficiency.		

(2) <u>Swine</u>--

Hygromycin B	Combination in	Indications for use	Limitations	Sponsor
in grams per ton	grams per ton			
(i) 12		Swine: For control of infestation	Withdraw 15 days before	000986
		of large roundworms (Ascaris	slaughter.	012286
		suis), nodular worms		017790
		(Oesophagostomum dentatum),		054771
		and whipworms (Trichuris suis).		
(ii) 12	Tylosin 10 to	Swine: For control of infestations	Feed continuously as follows:	000986
	100	of large roundworms (Ascaris	Animal weight (lbs.):	
		suis), nodular worms	Up to 4020 to 100 ¹	
		(Oesophagostomum dentatum),	41 to 10020 to 40 ¹	
		and whipworms (Trichuris suis);	101 to market weight. 10 to 20 ¹	
		growth promotion and feed	Withdraw 15 days before	
		efficiency.	slaughter. Tylosin as tylosin	
		-	phosphate as provided by No.	
			000986 in § 510.600 of this	
			chapter.	

¹Amount of Tylosin (g/t).

- 19. In § 558.311:
- a. In paragraph (e)(1)(ii), remove the entries for:
- i.Roxarsone 45.4 (0.005 pct);
- ii. Roxarsone 45.4 plus bambermycins 1 (0.00011 pct);
- iii. Roxarsone 45.4 plus lincomycin 2.0;
- iv. Roxarsone 45.4 plus bacitracin 10 to 25;
- v. Roxarsone 45.4 plus bacitracin 10 or 30; and
- vi. Roxarsone 45.4 plus bacitracin methylene disalicylate 50";
- b. In paragraph (e)(1)(xv), remove the entry for "Roxarsone 22.7 to 45.4"; and
- c. Revise paragraph (e)(5).

The revision reads as follows:

§ 558.311 Lasalocid.

* * * * *

- (e) * * *
- (5) Lasalocid may also be used in combination with:
- (i) Melengestrol acetate alone or in combination with tylosin as in § 558.342.
- (ii) [Reserved]
- 20. In § 558.325, revise paragraph (d)(3) to read as follows:

§ 558.325 Lincomycin.

* * * * *

- (d) * * *
- (3) Lincomycin may also be used in combination with:
- (i) Amprolium and ethopabate as in § 558.58.
- (ii) Clopidol as in § 558.175.
- (iii) Decoquinate as in § 558.195.
- (iv) Fenbendazole as in § 588.258.
- (v) Halofuginone as in § 558.265.
- (vi) Ivermectin as in § 558.300.
- (vii) Lasalocid sodium as in § 558.311.
- (viii) Monensin as in § 588.355.
- (ix) Nicarbazin alone and with narasin as in § 558.366.
- (x) Pyrantel as in § 558.485.
- (xi) Robenidine as in § 558.515.

- (xii) Salinomycin as in § 558.550.
- (xiii) Zoalene as in § 558.680.
- 21. In § 558.340, revise the section heading to read as follows:

§ 558.340 Maduramicin.

* * * * *

§ 558.355 [Amended]

- 22. In § 558.355:
- a. Remove and reserve paragraphs (f)(1)(ii), (vii), (x), (xi), (xii), (xv), (xvii), (xviii), (xix), (xx), (xxiii), (xxvi), and (xxvii);
 - b. Remove and reserve paragraphs (f)(4)(vi) and (vii); and
 - c. Remove the second instance of a paragraph designated (f)(4)(iv) (following (f)(4)(vii).

§ 558.363 [Amended]

- 23. In § 558.363:
- a. Remove and reserve paragraphs (a)(2), (a)(5) and (a)(6);
- b. Remove paragraphs (d)(1)(ii), (v), (vii), (viii), and (ix) and (d)(3)(iii) and (iv); and
- c. Redesignate paragraphs (d)(1)(iii) and (iv) as paragraphs (d)(1)(ii) and (iii), paragraph (d)(1)(vi) as paragraph (d)(1)(iv), and paragraphs (d)(1)(x) and (xi) as paragraphs (d)(1)(v) and (vi).

§ 558.366 [Amended]

- 24. In the table in § 558.366(d):
- a. In the "Nicarbazin in grams per ton" column, following the entry for "27 to 45", remove the row entries for:
 - i. Narasin 27 to 45, bacitracin methylene disalicylate 50, and roxarsone 22.7 to 45.4; and

- ii. Narasin 27 to 45 and roxarsone 22.7 to 45.4;
- b. In the "Nicarbazin in grams per ton" column, following the entry for "90.8 to 181.6 (0.01 to 0.02 pct)", remove the row entry for "Bacitracin methylene disalicylate 4 to 50 and roxarsone 22.7 to 45.4"; and
- c. In the "Nicarbazin in grams per ton" column, following the entry for "113.5 (0.0125 pct)", remove the row entries for:
 - i. Roxarsone 22.7 (0.0025); and
 - ii. Roxarsone 22.7 (0.0025) plus lincomycin 2 (0.0004)."
- § 558.460 [Amended]
 - 25. In § 558.460, remove and reserve paragraph (d)(2).
- 26. In § 558.515, in paragraph (d), remove the entries for "Bacitracin (as bacitracin methylene disalicylate) 50 and roxarsone 22.7 to 45.4", "Bacitracin (as bacitracin methylene disalicylate) 100 to 200 and roxarsone 22.7 to 45.4", and "Roxarsone 22.5 to 45.4 (0.005 percent)"; and revise the section heading to read as follows:

§ 558.515 Robenidine.

* * * * *

§ 558.530 [Removed]

27. Remove § 558.530.

§ 558.550 [Amended]

- 28. In § 558.550, remove and reserve paragraphs (d)(1)(ii), (iv), (v), (viii), (ix), (xii), (xiv), (xv), (xvii), (xviii), (xix), and (xxiv) and (d)(3)(iv), (vi), and (vii).
- § 558.555 [Amended]
 - 29. In § 558.555, remove paragraphs (d)(3), (d)(4), and (d)(8); and redesignate

paragraphs (d)(5), (d)(6), and (d)(7) as paragraphs (d)(3), (d)(4), and (d)(5), respectively.

§ 558.575 [Amended]

- 30. In § 558.575, remove and reserve paragraph (d)(1)(ii).
- 31. In § 558.680, revise paragraph (d) to read as follows:

§ 558.680 Zoalene.

* * * * *

(d) Conditions of use--(1) Chickens--

Zoalene in	Combination in	Indications for use	Limitations	Sponsor
grams/ton	grams per ton			
(i) 36.3 to 113.5		Replacement chickens: For	Grower ration not to be fed to birds	054771
		development of active immunity	over 14 weeks of age; as follows:	
		to coccidiosis.	_	

Growing conditions	Starter ration	Grower ration
	Grams per ton	Grams per ton
Severe exposure	113.5 (0.0125%)	75.4-113.5
		(0.0083%-0.0125%)
Light to moderate	75.4-113.5	36.3-75.4
exposure	(0.0083%-0.0125%)	(0.004%-0.0083%)

Zoalene in	Combination in	Indications for use	Limitations	Sponsor
grams/ton	grams per ton			
(ii) 36.3-113.5	Bacitracin	Replacement chickens: For	Feed continuously as sole ration as in	054771
	methylene	development of active immunity	subtable in item (i). Grower ration	
	disalicylate 4 to 50	to coccidiosis; and for increased	not to be fed to birds over 14 weeks	
		rate of weight gain and improved	of age.	
		feed efficiency.	Bacitracin methylene disalicylate as	
			provided by No. 054771 in	
			§ 510.600(c) of this chapter.	
(iii) 36.3-113.5	Bacitracin	Replacement chickens: For	Feed continuously as sole ration as in	054771
	methylene	development of active immunity	subtable in item (i). Grower ration	
	disalicylate 50	to coccidiosis; and as an aid in the	not to be fed to birds over 14 weeks	
		prevention of necrotic enteritis	of age.	
		caused or complicated by	Bacitracin methylene disalicylate as	
		Clostridium spp. or other	provided by No. 054771 in	
		organisms susceptible to	§ 510.600(c) of this chapter.	
		bacitracin.		
(iv) 36.3-113.5	Bacitracin	Replacement chickens: For	Feed continuously as sole ration as	054771
	methylene	development of active immunity	in subtable in item (i). To control	
	disalicylate 100 to	to coccidiosis; and as an aid in the	necrotic enteritis, start medication at	
	200	control of necrotic enteritis	first clinical signs of disease; vary	
		caused or complicated by	bacitracin dosage based on the	

		Clostridium spp. or other organisms susceptible to bacitracin.	severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 g/ton). Bacitracin methylene disalicylate as provided by No. 054771 in § 510.600(c) of this chapter.	
(v) 113.5		Broiler chickens: For prevention and control of coccidiosis.	Feed continuously as sole ration.	054771
(vi) 113.5	Bacitracin methylene disalicylate 4 to 50	Broiler chickens: As an aid in the prevention and control of coccidiosis; and for increased rate of weight gain and improved feed efficiency.	Feed continuously as sole ration. Bacitracin methylene disalicylate as provided by No. 054771 in § 510.600(c) of this chapter.	054771
(vii) 113.5	Bacitracin methylene disalicylate 50	Broiler chickens: For prevention and control of coccidiosis; and as an aid in the prevention of necrotic enteritis caused or complicated by <u>Clostridium</u> spp. or other organisms susceptible to bacitracin.	Feed continuously as sole ration. Bacitracin methylene disalicylate as provided by No. 054771 in § 510.600(c) of this chapter.	054771
(viii) 113.5	Bacitracin methylene disalicylate 100 to 200	Broiler chickens: For prevention and control of coccidiosis; and as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.	Feed continuously as sole ration. To control necrotic enteritis, start medication at first clinical signs of disease; vary bacitracin dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 g/ton). Bacitracin methylene disalicylate as provided by No. 054771 in § 510.600(c) of this chapter.	054771
(ix) 113.5	Bambermycins 1	Broiler chickens: As an aid in the prevention and control of coccidiosis; and for increased rate of weight gain and improved feed efficiency.	Feed continuously as sole ration. Do not feed to chickens over 14 weeks of age. Bambermycins as provided by No. 016592 in § 510.600(c) of this chapter.	016592
(x) 113.5	Lincomycin 2	Broiler chickens: As an aid in the prevention and control of coccidiosis; and for increased rate of weight gain and improved feed efficiency.	Feed continuously as sole ration. Do not feed to laying chickens. As lincomycin hydrochloride monohydrate provided by No. 054771 in § 510.600(c) of this chapter.	054771

(2) <u>Turkeys</u>--

Zoalene in	Combination in	Indications for use	Limitations	Sponsor
grams/ton	grams per ton			

Zoalene in	Combination in	Indications for use	Limitations	Sponsor
grams/ton	grams per ton			
(i) 113.5 to		Growing turkeys: For prevention	Feed continuously as sole ration.	054771
170.3		and control of coccidiosis.	For turkeys grown for meat	
			purposes only. Do not feed to laying	
			birds.	
(ii) 113.5 to	Bacitracin	Growing turkeys: For prevention	Feed continuously as sole ration	054771
170.3	methylene	and control of coccidiosis; and for	until 14 to 16 weeks of age. For	
	disalicylate 4 to 50	increased rate of weight gain and	turkeys grown for meat purposes	
		improved feed efficiency.	only. Do not feed to laying birds.	

Dated: February 3, 2014.

Bernadette Dunham,

Director,

Center for Veterinary Medicine.

[FR Doc. 2014-02617 Filed 02/26/2014 at 8:45 am; Publication Date: 02/27/2014]